Inspire Trust Co. N.A. Has $3.79 Million Holdings in DexCom, Inc. $DXCM

Inspire Trust Co. N.A. raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 16.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 57,039 shares of the medical device company’s stock after purchasing an additional 8,039 shares during the period. Inspire Trust Co. N.A.’s holdings in DexCom were worth $3,786,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of DXCM. CVA Family Office LLC increased its stake in shares of DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the last quarter. ORG Partners LLC increased its stake in shares of DexCom by 124.3% in the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 281 shares during the last quarter. Spire Wealth Management increased its stake in shares of DexCom by 113.8% in the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after acquiring an additional 305 shares during the last quarter. Aventura Private Wealth LLC bought a new stake in shares of DexCom in the 4th quarter valued at about $43,000. Finally, Rothschild Investment LLC increased its stake in shares of DexCom by 59.9% in the 3rd quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 245 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the sale, the insider directly owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. This represents a 6.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the sale, the director directly owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 32,871 shares of company stock valued at $2,306,638. 0.28% of the stock is owned by corporate insiders.

DexCom Price Performance

NASDAQ DXCM opened at $72.34 on Friday. The business has a 50 day simple moving average of $64.05 and a 200 day simple moving average of $66.39. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The stock has a market cap of $27.91 billion, a price-to-earnings ratio of 30.91, a PEG ratio of 1.16 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the business earned $0.32 EPS. DexCom’s revenue for the quarter was up 15.0% compared to the same quarter last year. Analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent analyst reports. Bank of America lowered their price target on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target for the company in a research note on Tuesday, March 24th. William Blair raised DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Barclays reaffirmed an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Finally, Benchmark initiated coverage on DexCom in a research note on Monday, May 11th. They issued a “buy” rating and a $77.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $82.42.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.